As a member of the B7 family, inducible co-stimulator ligand (ICOSLG) expressed on tumor cell has been reported to have an important role in tumor immunity. In this study, we sought to determine whether the expression of ICOSLG in mouse hematological malignancy cells influences GVL reaction after mouse allogeneic BMT. In our study, we analyzed the expression of ICOSLG in six mice hematological malignancy cell lines for the first time, and found that FBL3, A20 and P388 cells expressed high levels of ICOSLG. Then, we chose A20 cells as targets to construct a GVL model and study the effects on the GVL reaction by silencing the ICOSLG gene. The survival was analyzed. We found that in GVL model, mortality of interference groups was significantly delayed compared with the control group (P ¼ 0.0005). Our results indicate that knockdown of ICOSLG of mouse leukemic cells may significantly enhance GVL effect after allogeneic BMT.
INTRODUCTION
Allogeneic hematopoietic SCT (allo-HSCT) is a potentially curative therapy for hematological malignancies and GVL activity by alloreactive donor T cells has an important role in the prevention of post-transplantation tumor relapse. However, alloreactive donor T cells are also responsible for GVHD, a major cause of posttransplantation morbidity and mortality. Thus, a major challenge for allo-HSCT is to inhibit GVHD while maintaining the beneficial effects of T-cell-mediated GVL activity.
Optimal activation of T cells requires two signals: the first signal is delivered by the engagement of the T-cell receptor with the peptide-MHC complex on APC, and the second signal is a costimulatory signal. Inducible co-stimulator (ICOS) is a relatively recently characterized member of the B7 family of immuneregulatory ligands, which is involved in the co-stimulation of T cells and is expressed only on activated T cells. [1] [2] [3] The first member of the B7 family, B7-1, was identified over 20 years ago and revealed to have co-stimulatory function when ligated to the CD28 receptor on T cells. [4] [5] [6] [7] Several new members of the B7 family, such as B7-H1, ICOS ligand (LG), B7-H3 and B7-H4, have been identified since then. 8, 9 As the counter ligand of ICOS, a CD28-related molecule, ICOSLG is expressed on professional APC (such as DCs and B cells) and on some tumor cells (such as glioma cells and gastric carcinoma cells). [10] [11] [12] [13] ICOSLG is the only B7 family member that preferentially co-stimulates type 2T helper cell (Th2) responses, and interestingly, this unique molecule has a critical role in antitumor immunity. [14] [15] [16] ICOSLG expression on solid tumors (implanted-transfected tumors) aids in both NK mediated and CD8 þ CTL activation and killing. 16 Several studies using ICOSLGtransfected solid tumor cell lines found that ICOSLG induced CD8 þ cytotoxic lymphocyte-mediated tumor regression. 17, 18 Conversely, Tamura et al. 19 reported that the expression of ICOSLG in acute myeloid leukemic cells was associated with a shorter survival time. Another study showed that human myeloma cell lines commonly expressed B7.2 and ICOSLG molecules. Plasma cells expressing ICOSLG were observed in myeloma patients alone, while not in patients with monoclonal gammopathy of unknown significance or hematologically normal individuals and that expression of these molecules was associated with a growth advantage in vitro. 20 Furthermore, this study provided evidence that these molecules were involved in the pathophysiology of multiple myeloma.
ICOSLG is a positive co-stimulatory molecule that has a primary role in Th2 responses. 21 Furthermore, ICOS blockade reduces the production of Th2 cytokines but not type 1T helper cell cytokines. 22 Therefore, the ICOSLG-ICOS signal most likely favors the induction of Th2-type responses, and thus may be involved in the negative regulation of cell-mediated immune responses against tumors. The role of ICOSLG expressed on hematological neoplasms in tumor immunity is not clear now. Although it have revealed that a variety of human hematological cell lines, leukemic cells from acute myeloid leukemia patients, lymphoma cells and plasma cells express ICOSLG, 19, 23 it has not been reported whether ICOSLG molecules are expressed in cell lines of mouse hematological malignancies.
In our previous study, 24 we choose mouse hematological malignancies as objects and used flow cytometry to analyze the expression of ICOSLG in six mouse hematological neoplasm cell lines. We found that FBL3, A20 and P388 cells expressed high levels of ICOSLG, whereas L6565, YAC-1 and EL4 cells showed little to no expression of ICOSLG. Based upon ICOSLG expression, we chose one erythroid malignancy cell line(FBL3) and one lymphocytic malignancy cell line(A20) as target cells to determine whether the blockade of ICOSLG influences cytotoxicity in allogeneic mixed lymphocyte-hematological neoplasm cell reaction. We directly blocked the ICOSLG molecule with anti-mouse ICOSLG antibody and demonstrated that blocking ICOSLG was sufficient to enhance the cytotoxicity of alloreactive T cells against mouse hematological neoplasm cells. Our data also suggest that when ICOSLG was blocked, production of the two Th2 cytokines (IL-4 and IL-10) noticeably decreased, but the blockade did not significantly influence the production of the two type 1T helper cell (IFN-g and IL-2) cytokines.
Previous studies showed that ICOS blockade may be able to inhibit or treat GVHD while GVL activity is slightly diminished. [25] [26] [27] However, as far as the ICOSLG molecule that expressed on leukemic cells is concerned, which role it has on the GVL reaction after allogeneic BMT has not yet been reported. A study has revealed that the administration of soluble ICOSLG-Fc may delay tumor growth in some mouse hematological neoplasms in syngeneic hosts. 28 In this study, we analyzed the expression of ICOSLG in FBL3, A20 and P388 cell lines again, and chose A20 as target cells to construct a GVL model. Then, we introduced shRNA into A20 cells to knockdown the ICOSLG gene to represent its effect on the GVL reaction after allogeneic BMT for the first time.
MATERIALS AND METHODS

Cell lines and cell culture
Three mouse cell lines derived from hematological malignancies were used. A20, FBL3 and P388 were all obtained from the Cell Bank of Type Culture Collection, Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). These cells were cultured in RPMI 1640 medium with 10% FCS, 100 units/mL penicillin, 100 mg/mL streptomycin and 2 mM L-glutamine.
Mice and allo-BMT C57BL/6 (B6) and BALB/c mice were obtained from the Shanghai SLAC Laboratory Animal Co., Ltd (Shanghai, China). Mice used in allo-HSCT experiments were between 6 and 8 weeks of age. Referring to the experimental method of our colleagues Tao et al., 29 BM cells were removed aseptically from femurs and tibias of donor mice. Splenocytes were obtained by centrifugation in lymphocyte-M. T cells were calculated in splenocytes. Cells (5 Â 10 6 BM with or without 4.5 Â 10 5 splenic T lymphocytes) were resuspended in PBS medium and transplanted by tail vein infusion (0.25 mL total volume) into lethally irradiated recipients on day 0. Before transplantation, on day 0, recipients received 9.0 Gy TBI ( Construction of expression plasmids ICOSL-specific siRNAs were designed with BLOCK-IT RNAi Designer (at https://rnaidesigner.invitrogen.com/rnaiexpress/), and synthesized using the chemical synthesis method by GeneChem Co. (Shanghai, China). Plasmids expressing siRNA were under the control of the human U6 promoter in pGSci/U6 vector (GeneChem Co.). The pGSci vector contains the H1 promoter driving the siRNA cassette together with a CMV-driven coral EGFP (EGFP) cDNA and neomycin-resistant gene. The complementary sequences of siRNA were as follows: 5 0 -CACTCAGCTTCACAACATCAATT CAAGACGTTGATGTTGTGAAGCTGAGTG-3 0 , which forms stem-loop structured siRNA, targeted to Mus ICOS ligand (ICOSLG) mRNA (targeted sequence: 5 0 -CTCAGCTTCACAACATCAA-3 0 ), with loop sequences of 5 0 -TTCAAGACG-3 0 . A non-silencing siRNA was used as a negative control. The complementary sequences of this control siRNA were as follows:
Real-time reverse transcription-PCR
We used the RNAiso Plus kit for RNA isolation, the PrimeScript RT reagent kit for reverse transcription and the SYBR Premix Ex Taq kit for real-time PCR (Takara Bio Inc., Shiga, Japan). All procedures were carried out according to the manufacturer's instructions. The real-time PCR was performed on cDNA from all six cell lines using an ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The primers used to amplify a 165-bp product of B7-H2 were 5 0 -TGG AAG AGG TGG TCA GGC-3 0 (forward) and 5 0 -TTA GGC TAT TGT CCG TTG-3 0 (reverse). B7-H2 mRNA expression was normalized to that of b-actin, and the primers used to amplify a 266-bp product of b-actin were as follows: 5 0 -GTC CCT CAC CCT CCC AAA AG-3 0 (forward) and 5 0 -GCT GCC TCA ACA CCT CAA C CC-3 0 (reverse).
IHA20 sort, in vitro transfection and G418 selection ICOSLG-positive A20 cells were sorted using a FACS Vantage cell sorter according to the manufacturer's instructions (BD Biosciences). Those cells were diluted for a limiting value. The cells that express ICOSLG highly were selected by inverted microscope and cultured for days. We called these cells IHA20 (ICOSLG highly expressed in A20 cells). IHA20 cells were plated on 24-well culture plates (at a density of 7 Â 10 5 cells/well). After an overnight incubation, transfection of pGSci or pGSci-shRNA was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) at a final concentration of 2 mg pDNA/mL according to the manufacturer's instructions. In brief, 1 mg ICOSLG-specific shRNA expressing plasmids pGScishRNA, or negative control pGSci-DNA, was mixed with 3 mg Lipofectamine 2000 (Invitrogen), in 500uL serum-free medium per well. At 8 h after transfection, the medium was replaced by fresh RPMI-1640 medium with 10% FBS and cultured for 48 h. Those cells were selected using 800 ug/mL of G418 for 14-20 days to obtain a clone expressing the highest EGFP and neomycin-resistant activity.
The proliferation of selected cells was measured by cell count in vitro
In all, 1.0 Â 10 4 cells were plated onto a 24-well multiwell plate in 1 mL of medium consisted of RPMI 1640 supplemented with 10% FCS. The number of the cells of the three samples was calculated with counting plate at the same time everyday for 6 days. The proliferation curves of the three different cell populations IHA20, IHA20-control shRNA and IHA20-shRNA were drawn.
Tumor induction and the erect of GVL model
To assess the effects of ICOSLG gene knockdown on GVL activity of alloreactive T cells, we constructed the GVL model: C57B6-BALB/c with IHA20. In this model, animals received 8 Â 10 4 leukemia cells intravenously in a separate injection on day 0 of allo-HSCT, and a low dose of donor splenic T-lymphocytes cells (4.5 Â 10 5 ) was used to decrease GVHD mortality and allow for a better measurement of GVL activity. Survivals were monitored daily. The cause of death was determined by necropsy and histopathology. Briefly, all animals with macroscopic liver/spleen metastasis at autopsy were recorded as tumor deaths. The spleens and livers from animals that did not exhibit any gross evidence of tumor were analyzed by histopathology for evidence of microscopic tumor, and cause of death was subsequently determined. If no evidence of tumor was detected and the animals displayed signs of GVHD, the cause of death was established as GVHD. If tissues were lysed at autopsy the cause of death was labeled as not analyzed. In addition, mice splenic lymphocytes of control groups and interference groups were obtained at day 24. The percentage of EGFP-positive cells in the two groups was calculated.
Statistical analysis
Comparison between groups was done by analysis of variance. The statistical significance of differences was determined by Student's twotailed t-test in two groups and one-way analysis of variance in multiple groups with the SAS 9.1.3 software (Shanghai, China). The Mantel-Cox logrank test was used for survival data. P-values of o0.05 were considered to be statistically significant.
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RESULTS
ICOSLG is highly expressed in three mouse leukemic cell lines
Using flow cytometry, we found that FBL3, A20 and P388 cells expressed high levels of ICOSLG. The rates of ICOSLG þ cells were as follows: 85.22 ± 0.24% of FBL3 cells, 47.13 ± 0.44% of A20 and 21.56±0.56% of P388 (Figure 1a) . These results have been confirmed by real-time reverse transcription-PCR (Figure 1b) .
Silencing of ICOSLG by shRNA After sorting with a FACS Vantage cell sorter, the cells that express ICOSLG highly were selected and cultured for 14 days. The positive rate of IHA20 was steady at 85.22±2.04%. After transfection and G418 selection, the ICOSLG-positive rates of IHA20-control shRNA and IHA20-shRNA was 84.33 ± 4.11 and 16.01 ± 2.14%, respectively, (Po0.01; Figures 2a-c) , ICOSLG mRNA in shRNA-transfected IHA20 cells reduced (95.78±0.18)% compared with that in the control (Po0.01; Figure 2d ). The proliferation was calculated also by cell counting and there were no significant differences among IHA20, IHA20-control shRNA and IHA20-shRNA groups (P40.05; Figure 3 ).
Knock-down of ICOSLG gene of mice A20 cell may significantly delayed mortality enhance in our GVL model In this GVL model, we observed that all the mice in the group for GVHD that received alloHSCs and donor splenic lymphocytes cells were still alive at the end of our observation period (Figure 4a) . We also observed that no mortality without tumor challenge in mice that received IHA20-control shRNA or IHA20-shRNA cells (data not shown).
Mortality of interference groups for GVL that received alloHSCs with donor splenic lymphocytes and IHA20-shRNA cells was significantly delayed compared with control groups for GVL that received alloHSCs with donor splenic lymphocytes and IHA20-control shRNA cells, while the mortality of the latter one was significantly delayed compared with the tumor challenge group that received alloHSCs and IHA20-control shRNA cells (Figure 4a ). 
Effects of ICOSLG in the GVL reaction B Wang et al
Knockdown of ICOSLG gene of mice A20 cell may significantly delay tumor progression in our GVL model Spleens of interference groups and control groups were removed and lymphocytes were obtained by centrifugation in lymphocyte-M at day 24. EGFP-positive cells (leukemia cells) were analyzed on a FACScan cytometer. The percentage of EGFP-positive cells in the two groups is (17.65 ± 0.07)% and (2.10 ± 0.03), respectively, (Figures 4b and c) . Mouse liver and spleen were paraffin embedded, sectioned, and hematoxylin and eosin stained. Figure 4d is the representative photograph of infiltration of the liver by leukemia cells in interference groups compared with that in control groups.
DISCUSSION
We introduced ICOSLG-specific shRNA to knockdown the ICOSLG gene of IHA20 cell. The ICOSLG-positive rates reduced from 84.33±4.11 to 16.01±2.14% and ICOSLG mRNA reduced (95.78 ± 0.18)% than before. In our GVL model, mortality of interference groups for GVL was significantly delayed compared with control groups for GVL. We also observed that mortality was no difference between the group received alloHSCs with IHA20-shRNA and the group received alloHSCs with IHA20-control shRNA cells. These indicate that it is not the difference of the cell between IHA20-control shRNA and IHA20-shRNA but the GVL effect that made mortality difference between interference groups for GVL and control groups for GVL. We all know that recognition by donor T cells of leukemiarestricted antigens would require either direct antigen processing and presentation by the leukemia, or presentation of leukemia antigens by hostor donor-derived professional APC. The naive T cells were primed to the Th2 cells after direct antigen presentation by the leukemia and conjunction of ICOS and ICOSLG. It is favorable for leukemia cells to grow with high concentration of Th2 cytokine around them. We blocked the direct antigen presentation path by silencing of its ICOSLG gene to inhibit the growth of leukemia and so enhance the GVL effect.
Hubbard et al. 27 reported that alloreactive ICOS À / À donor T cells induce less GVHD while GVL activity is slightly diminished. In this study, not only direct antigen presentation path but also indirect antigen presentation path was blocked. The GVL effect through presentation of leukemia antigens by APC cannot achieve and this partly covered the enhancement to GVL through direct path.
Yu et al. 31 found that recipients of ICOS À / À CD4 þ T cells exhibited significantly less GVHD morbidity and delayed mortality while recipients of ICOS À / À CD8 þ T cells exhibited significantly The graph shows the average of three separate experiments. We found that no significant influence to cell proliferation was observed in IHA20-shRNA cells and IHA20-control shRNA cells (P40.05). There was no significant influence between IHA20-shRNA cells and IHA20 cells (P40.05). Cell growth curve was plotted against time. enhanced GVHD morbidity and accelerated mortality. ICOS þ CD4 þ T cells might have a more important role in GVHD. In recent years, Strauss et al. 32 found that CD4 þ CD25 þ Treg in tumor-infiltrating lymphocytes expressed ICOS, while Treg in PBMC had low ICOS expression. ICOS high Treg upregulated Treg markers and mediated stronger suppression relative to ICOS low Treg partly mediated via IL-10 and transforming growth factor-b.
We all know that the cytokine environment in vivo is very complex, and the change of cytokines when ICOS/ICOSLG blocked still remains controversial in different disease models. 27 Also, the GVL reaction does not only depend on cytokines. Why knockdown of ICOSLG gene of mice leukemic cell significantly enhances GVL effect after allogeneic BMT perhaps needs to be studied further.
CONCLUSIONS
In summary, our results indicate that knockdown of ICOSLG gene of mice leukemic cell may significantly enhance GVL effect after allogeneic BMT. In our study, it is the ICOSLG molecule expressed on leukemic cell that we focused on. Just as previous studies showed that ICOS blockade may be able to inhibit or treat GVHD, 26, 33 our study indicates that ICOSLG blockade may provide a new strategy to enhance the GVL effect in allogeneic PBSC transplantation.
